ANILERIDINE PHOSPHATE

US Previously Marketed

First approved in 1957

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N2O2.H3O4P
Molecular Weight	450.4651
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OP(O)(O)=O.CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C3=CC=CC=C3

InChI

InChIKey=FLQCEKVTYABVSH-UHFFFAOYSA-N

InChI=1S/C22H28N2O2.H3O4P/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18;1-5(2,3)4/h3-11H,2,12-17,23H2,1H3;(H3,1,2,3,4)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13815278

Aniledrine is a narcotic pain reliver. The drug was prescribed as an analgesic in anaesthesia (Leritine brand name), however, it is no longer available on the market. Although the exact mechanism is not fully understood, aniledrine appears to elicit its action by binding to endorphine receptors in CNS.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13815278	Curative		Approved 8429	LERITINE Approved Use Unknown

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% OTHER https://go.drugbank.com/drugs/DB00913			ANILERIDINE unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
450 mg multiple, oral (total daily dose\|max) Studied dose Dose: 450 mg Route: oral Route: multiple Dose: 450 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319	unhealthy, 41 n = 1 Health Status: unhealthy Condition: Pain Age Group: 41 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319	Disc. AE: Delirium... AEs leading to discontinuation/dose reduction: Delirium Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319

AEs

AE	Significance	Dose	Population
Delirium	Disc. AE	450 mg multiple, oral (total daily dose\|max) Studied dose Dose: 450 mg Route: oral Route: multiple Dose: 450 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319	unhealthy, 41 n = 1 Health Status: unhealthy Condition: Pain Age Group: 41 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7541439 Page: p.319

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:61203	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:61203
ZINC	ZINC000000608179	http://zinc15.docking.org/substances/ZINC000000608179

PubMed

Title	Date	PubMed
Contact dermatitis to anileridine.	1980 Dec	6894270
Anileridine-induced delirium.	1995 May	7541439
Electronic-topological study of the structure-activity relationships in a series of piperidine morphinomimetics.	2002 Aug	12171562
Metabolic fate of orally administered phyllodulcin in rats.	2004 Sep	15387672
Synthesis, characterization and antimicrobial properties of a Co(II)-phthalylsulfathiazolate complex.	2010 Dec	20526731

Patents

Sample Use Guides

In Vivo Use Guide

Aniledrine is administred either orally (in form of hydrochloride salt)

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

ANILERIDINE PHOSPHATE

Common Name

English

Anileridine phosphate [WHO-DD]

Common Name

English

ANILERIDINE PHOSPHATE [ORANGE BOOK]

Common Name

English

ANILERIDINE PHOSPHATE [MART.]

Common Name

English

LERITINE PHOSPHATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C241